AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

Asthma is an incurable inflammatory ... a difficult time launching plenty of growth products in the future. That's why analysts are anticipating AstraZeneca will deliver 15.3% annual earnings ...

They're produced by an industry-leading manufacturer, but one U.S. agency warns of a defect concerning this well known ...

Drugmaker AstraZeneca will cap out-of-pocket ... 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including ...

You may report side effects related to AstraZeneca products. Strong cytochrome P450 ... severe hepatic disease should be closely monitored Asthma is a chronic, inflammatory respiratory disease ...

For AstraZeneca, the new product could breathe ... Albuterol rescue inhalers are already available to asthma patients. These products alleviate acute systems but do not address the underlying ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ... We sell different types of products and services to both ...

March 18 (Reuters) - Drugmaker AstraZeneca (AZN.L), opens ... would cap out-of-pocket costs for its inhaler products for chronic lung disease and asthma to $35 per month, starting June 1.

The Allergy & Asthma Network praised three major pharmaceutical companies, AstraZeneca, Boehringer Ingelheim and GSK, that announced they will enact a $35 price cap on their inhaler products.

Appearing as if he is trailing along behind an asthma patient ... which was interesting timing considering AstraZeneca also announced that, effective June 1, out-of-pocket costs for all of its inhaler ...

WILMINGTON, Del. - AstraZeneca (Market cap: $219.79B), a prominent player in the pharmaceuticals industry with an "GREAT" financial health rating according to InvestingPro, announced its triple ...